{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Evaluating CAR-T Therapy in Patients with Refractory B-Cell Lymphomas

Activity Steps

Purpose of Activity

To provide information on the use of autologous chimeric antigen receptor T-cell therapy (CAR-T) in patients with refractory B-cell lymphomas.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Analyze the results of the Phase 2 trial of axicabtagene ciloleucel (axi-cel) for patients experiencing either resistance to primary or salvage-setting chemoimmunotherapy or a post-autologous stem cell transplant (ASCT) relapse.
  2. Assess implications for future research avenues and applications of this treatment.
Price: $12.95


  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Test Code: OT0818
Published: Aug 2018
Expires: 9/3/2021
Sources: Oncology Times
Required Passing Score: 7/10 (70%)
Authors: Richard Simoneaux
Categories: Cancer , Oncology
Specialties: Oncology